HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leiner/PFI

This article was originally published in The Tan Sheet

Executive Summary

Leiner Health Products completes its acquisition of "substantially all" assets related to Pharmaceutical Formulations' (PFI) "solid dose pharmaceutical products business" for $23 mil. in cash, Leiner announces Sept. 26. In addition to opportunities in pain management in both OTC and supplement areas, the acquisition "allows us to enhance our contract manufacturing capabilities and expands our OTC product offering and customer base," CEO Robert Kaminski says. Leiner concurrently announces that it has amended its credit agreement, which "will enhance the company's flexibility to manage the business and support the acquisition." Leiner's plans to acquire PFI's assets were made known shortly after the Edison, N.J.-based company declared bankruptcy in July (1"The Tan Sheet" July 18, 2005, p. 4)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS127364

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel